Iovance Biotherapeutics
Focus: Iovance Biotherapeutics is a cell therapy specialist focused on adoptive cell therapies (primarily tumor-infiltrating lymphocytes) for solid tumors and hematologic malignancies. The company operates as a mid-cap biotech with a concentrated pipeline targeting melanoma, lung cancer, and multiple other oncology indications.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Open Jobs
34+86 this month
Hot — 101 jobs added in 30d
Net +86 (101 new, 15 removed). Aggressive expansion phase.
Should You Work at Iovance Biotherapeutics?
AI assessmentIovance is an attractive early-to-mid-stage bet for professionals seeking deep expertise in cutting-edge cell therapy with scale-up infrastructure, but career stability depends entirely on Phase 3 trial outcomes and capital availability.
Why Work Here
- Deep specialization in adoptive cell therapy—an emerging immunotherapy modality with significant clinical validation potential and fewer competitors than checkpoint inhibitors.
Data completeness
2/9 — Limited
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Ipilimumab
Metastatic MelanomaClinical Trials (1)
NCT01701674Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
N/AHelp build intelligence for Iovance Biotherapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.